All posts tagged pharmaceuticals
Irish biotech group Elan puts itself on the block after advising against hostile bid from RP Management
Irish biotechnology firm Elan Corp plc (NYSE:ELN) said it was launching a formal sale given expressions of interest it had received and would invite hostile suitor RP Management LLC (Royalty Pharma) to take part in the process. Elan also once …
Pharmaceuticals firm Novartis denies talk on bid for generic drug maker Actavis
Swiss pharma major Novartis AG (VTX:NOVN) does not intend to pursue a takeover of US drugmaker Actavis Inc (NYSE:ACT), a company spokesperson told Reuters, refuting a previous report
Actavis says discusses merger with Warner Chilcott
US speciality pharmaceutical company Actavis Inc (NYSE:ACT) said it had engaged in early-stage talks to potentially combine with Irish sector player Warner Chilcott plc (NASDAQ:WCRX). The US firm noted
Pharmaceuticals giant GSK increase stake in Indian healthcare unit to 73%
Irish pharmaceutical firm Warner Chilcott ends talks with possible buyers
Dublin-based speciality pharmaceuticals group Warner Chilcott plc (NASDAQ:WCRX) said it had terminated talks with potential buyers and decided instead to pursue other alternatives to boost shareholder value. At the
British drugs giant GSK could announce a deal for HGS today
British drugmaker GlaxoSmithKline Plc (LON:GSK) is seen to increase to some USD14.00 (EUR11.43) a share, or around USD2.8bn in total, from USD13.00 per share, its bid to buy
Genova Diagnostics buys Metametrix
US diagnostic testing specialist Genova Diagnostics Inc said it had acquired clinical laboratory tests provider Metametrix Inc for an undisclosed sum. Following the transaction, Metametrix's chief executive officer Dr
Human Genome recommends stockholders reject GSK’s bid
US biopharmaceutical firm Human Genome Sciences (NASDAQ:HGSI), or HGS, reiterated its advice to shareholders not to tender their stock to the $13.00 (EUR10.30) a share hostile takeover offer
Bristol-Myers Squibb agrees $5.3bn deal to acquire Amylin
US pharmaceutical group Bristol-Myers Squibb Co (NYSE:BMY) said it had made an agreement to buy diabetes-focused biopharmaceutical firm Amylin Pharmaceuticals Inc (NASDAQ:AMLN) at U$31.00 (€24.50) in cash per
Upsher-Smith takes full control of London-listed Proximagen
US drugmaker Upsher-Smith Laboratories Inc (USL) has agreed to buy the rest of the shares not yet owned in Proximagen Group Plc (LON:PRX) in a deal valuing the
Follow us on
vMan: The PND in the photo is a Garmin......
Mel Giles insolvency practitioner: "The remaining UK-manufactured vehicles are exported, with more than e...
Counterspin: Boeing's stock may be soaring, but their disingenuous and manipulative...
Claire: Great tip, thanks...
Mark (ISPreview UK): The £530m broadband roll-out was actually first announced back in late...